02 November 2026
As of 1 September 2026, medical practitioners and authorised nurse practitioners no longer need specialist hepatitis B s100 prescriber accreditation to prescribe PBS-subsidised hepatitis B antiviral treatment for eligible patients.
Hepatitis B medicines, including first-line antiviral therapies such as entecavir and tenofovir, remain listed under the PBS Section 100 Highly Specialised Drugs Program.
While the accreditation requirement has been removed, the relevant patient and prescriber eligibility criteria under PBS restrictions continue to apply for patients to receive PBS-subsidised treatment.
The change provides an opportunity to improve access to treatment for people living with chronic hepatitis B and support hepatitis B management within primary care and community-based health services.
Clinical support and resources
Clinicians can access hepatitis B management education, clinical decision-support tools and specialist advice through ASHM Health, including:
- Important changes to Hepatitis B s100 prescriber accreditation – information about the prescribing changes here.
- Hepatitis B Toolkit for Clinicians – resources to support hepatitis B management here.
- Decision Making in Hepatitis B – clinical decision-support resource here.
- Hepatitis B Advanced Management and Prescribing education – further education for clinicians can be found here.
- ASHM Hepatitis B Prescriber Map – find clinicians experienced in hepatitis B management for clinical support or referral where required here.
- HepLink – free and confidential hepatitis B information and support for patients, families and healthcare providers on 1800 437 222 or via HepLink. Find further details here.
